Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Other

E.i. Dupont De Nemours and Company

Dupont Pharmaceuticals Company

Bristol-myers Squibb Pharma Corporation

Jingwu Duan

Bin Jiang

Zhonghui Lu

T G Murali Dhar

Carl P Decicco

Chu-Biao Xue

Thomas P Maduskuie, Jr

James Edward Sheppeck

Matthew Ernst Voss

David S Weinstein

Robert J Cherney

Hai-Yun Xiao

Gregory R Ott

William John Pitts

Andrew J Tebben

Stephen T Wrobleski

Bingwei Vera Yang

Shuqun Lin

John T Hynes

Steven H Spergel

John L Gilmore

Hong Wu

Junqing Guo

Joseph Barbosa

Jagabandhu Das

Ping Chen

Douglas G Batt

Chunjian Liu

Joseph Anthony Tino

Milind Rajopadhye

John S Tokarski

Percy H Carter

William F DeGrado

Xiao-Tao Chen

Qingjie Liu

George V Delucca

Lihua Chen

Zelda Rakowitz Wasserman

Arun Kumar Gupta

Ananta Karmakar

David Marcoux

Hua Gong

Carolyn A Weigelt

David J Nelson

Qing Shi

James Kempson

Gregory D Brown

Xiao Tao Chen

Murali T G Dhar

Khehyong Ngu

Stephen E Mercer

Ronald L Magolda

John A Barrett

Anurag S Srivastava

Lyndon A M Cornelius

Lidia M Doweyko

Irina Cipora Jacobson

George V De Lucca

Ian Mangion

Myra Beaudoin Bertrand

Tg Murali Dhar

Xiaohua He

Arthur M Doweyko

Ying Song

Bryan W King

Chu-Bio Xue

Elizabeth Arner

David Nelson

Ning Li

Alan P Carpenter Jr

Lyndon AM Cornelius

Murali TG Dhar

TG Murali Dhar

Ian K Mangion

There are described ROR&#x3b3; modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders.

ROR &#x3b3; modulators

Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CRor N; B is CRor N; D is CRor N; Lis &#x2014;(CRR)&#x2014;; Lis &#x2014;(CRR)&#x2014;; and X, Z, R, R, R, R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of TNF&#x3b1;, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases. 

Heterocyclic compounds useful as modulators of TNF alpha

There are described ROR&#x3b3; modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders.

Tricyclic sulfones as ROR&#x3b3; modulators

Disclosed are compounds of Formula (I) or a salt thereof, wherein: Ring A is 3- to 6-membered carbocyclic or heterocyclic ring; X is CRor N; Y is &#x2014;(CRR)&#x2014;; Z is &#x2014;(CRR)&#x2014;; and q, R, R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of TNF&#x3b1;, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases. 

Cyclic compounds useful as modulators of TNF &#x3b1;

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: &#x2014;(CR3R3)2-5-, &#x2014;(CR3R3)x-Y&#x2014;(CR3R3)y-, &#x2014;Y&#x2014;(CR3R3)2-3-Y&#x2014;, &#x2014;CR3R3-Y&#x2014;(CR3R3)2-Y&#x2014;, &#x2014;Y&#x2014;(CR3R3)2-Y&#x2014;CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF&#x3b1;, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Tricyclic heterocyclic compounds useful as inhibitors of TNF

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: (i) &#x2014;(CRR)&#x2014;; (ii) &#x2014;(CRR)&#x2014;Y&#x2014;(CRR)&#x2014;; Or (iii) &#x2014;Y&#x2014;(CRR)&#x2014;Y&#x2014;; and Y, R, R, R, R, R, R, x, and y are defined herein. Also disclosed are methods of using such compounds as modulators of TNF&#x3b1;, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted tricyclic heterocyclic compounds

Described are ROR&#x3b3; modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders. 

Carbocyclic sulfone ROR&#x3b3; modulators

Described are ROR&#x3b3; modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders. 

ROR&#x3b3; modulators

Cyclohexyl sulfone ROR&#x3b3; modulators

Described are ROR&#x3b3; modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders. 

Heterocyclic sulfone ROR&#x3b3; modulators

Described are ROR&#x3b3; modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR&#x3b3; activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR&#x3b3; activity, for example, autoimmune and/or inflammatory disorders.

Pyrrolidinyl sulfone ROR&#x3b3; modulators

The present application describes modulators of MCP-1 or CCR-2 of formula 

Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity

Growing community of inventors

Yardley, PA, United States of America

Jingwu Duan